Bausch & Lomb vs Dexcom
Bausch & Lomb and Dexcom are similar in size: $5.10bn and $4.66bn of revenue in their latest fiscal years. Dexcom grew faster (15.6% against 6.5%). Dexcom kept more of each dollar of sales as profit: a net margin of 17.9% against -7.1%. Dexcom carries less debt relative to equity (45.2% against 79.2%).
| Latest fiscal year | Bausch & LombBLCO, 2025 | DexcomDXCM, 2025 |
|---|---|---|
| Revenue | $5.10bn | $4.66bn |
| Revenue growth | 6.5% | 15.6% |
| Net income | −$360m | $836m |
| Operating margin | 2.2% | 19.6% |
| Net margin | -7.1% | 17.9% |
| Return on equity | -5.6% | 34.5% |
| Free cash flow | −$66.0m | $1.08bn |
| Cash | $383m | $918m |
| Total debt | $5.11bn | $1.24bn |
| Debt to equity | 79.2% | 45.2% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $500m |
| Employees | — | 11,100 |
| Market value | $7.14bn | $31.01bn |
| Price vs our value range | — | Within our value range |
| Moat score | 19 (Weak) | 56 (Moderate) |
| Insider trades, 12 months | 9 buys, 4 sales | 2 buys, 32 sales |